Archives: Agenda

Concept: This interactive workshop introduces the AI Rights Initiative as a practical framework that sponsors, CROs, and recruitment vendors can use to evaluate AI systems used in oncology trials. Through a short panel discussion and facilitated table conversations, participants will explore how recruitment algorithms, digital tracking technologies, and patient data analytics intersect with patient rights and regulatory responsibilities

Takeaway: Attendees will leave with practical governance questions that can help organizations implement AI responsibly while maintaining patient trust in clinical research

• Understanding the current investment climate to target and pitch your study to the right investors
• Reducing fundraising timelines through effective investor communication to ensure complex study plans are understood
• How to expand your professional network to connect with new investors and secure funding for oncology clinical trials

• Overview of pathology and the expertise of pathologists in tissue evaluation and procurement for clinical trial success
• Best practices for tissue and liquid biopsy selection, handling, and quality assurance, including considerations for ctDNA and MRD testing.
• Case-based examples demonstrating optimal specimens for clinical trial enrollment, as well as common pitfalls in tissue and ctDNA/MRD workflows leading to case failures.
• How Natera harnesses real-world data from its commercial pipeline to accelerate clinical trial advancement and enrollment

• Incorporating patient-centric strategies in trial designs to reduce patient burden
• Overview of new innovations that can be included in studies to increase patient centricity
• Adopting a patient-first mindset when designing trial protocols for patient-friendly studies

• You don’t have a recruitment problem, you have a design problem
• Most delays are designed into the protocol from day one
• Patient burden is created on paper before it’s felt in reality
• Fix the protocol → fix recruitment, timelines, and outcomes
• AI enables right-first-time trial design at scale

• Understanding the unique challenges biotechs face to reduce roadblocks and ensure clinical trial success
• Weighing up in-house capacity versus budget to ensure effective outsourcing decisions
• Working with limited resources to ensure regulatory compliance and minimize roadblocks